2025 United Kingdom 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report
Description
The 2025 United Kingdom 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in the United Kingdom are Pfizer Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., and Sanofi. Pfizer leads with its Prevnar vaccine brand, including Prevnar 13 and Prevnar 20, both pneumococcal conjugate vaccines approved for use in the UK and Europe, with ongoing regulatory endorsements such as EMA marketing authorization for the 20-valent vaccine. GSK is also a top player, with longstanding involvement in pneumococcal vaccines and significant market share in the UK and Europe. Merck & Co. actively competes with vaccines like its recently FDA-approved Capvaxive and has a strong presence in the UK market. Sanofi participates with its pneumococcal vaccine candidates and recent collaborations to enhance its vaccine portfolio, marking it as a significant competitor in the UK and global markets.
In the UK, these companies benefit from a market focused on pneumococcal conjugate vaccines, which dominate in usage due to better efficacy in children and high-risk groups. The UK market was worth approximately USD 158.6 million in 2023 and is expected to grow rapidly, driven by increasing pneumococcal disease incidence and immunization efforts. Pfizer’s recent introduction of PCV15 (Vaxneuvance) approved for young children and plans for broader-valent vaccines stimulate competition and innovation. GSK, Merck, and Sanofi also focus on expanding vaccine coverage and advancing newer formulations to address pneumococcal disease strains prevalent in the region. The collaborative environment and regulatory support encourage ongoing product development and vaccine accessibility improvements throughout the UK.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in the United Kingdom are Pfizer Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., and Sanofi. Pfizer leads with its Prevnar vaccine brand, including Prevnar 13 and Prevnar 20, both pneumococcal conjugate vaccines approved for use in the UK and Europe, with ongoing regulatory endorsements such as EMA marketing authorization for the 20-valent vaccine. GSK is also a top player, with longstanding involvement in pneumococcal vaccines and significant market share in the UK and Europe. Merck & Co. actively competes with vaccines like its recently FDA-approved Capvaxive and has a strong presence in the UK market. Sanofi participates with its pneumococcal vaccine candidates and recent collaborations to enhance its vaccine portfolio, marking it as a significant competitor in the UK and global markets.
In the UK, these companies benefit from a market focused on pneumococcal conjugate vaccines, which dominate in usage due to better efficacy in children and high-risk groups. The UK market was worth approximately USD 158.6 million in 2023 and is expected to grow rapidly, driven by increasing pneumococcal disease incidence and immunization efforts. Pfizer’s recent introduction of PCV15 (Vaxneuvance) approved for young children and plans for broader-valent vaccines stimulate competition and innovation. GSK, Merck, and Sanofi also focus on expanding vaccine coverage and advancing newer formulations to address pneumococcal disease strains prevalent in the region. The collaborative environment and regulatory support encourage ongoing product development and vaccine accessibility improvements throughout the UK.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
